Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Lombardi Borgia, A."'
Publikováno v:
In European Journal of Pharmaceutics and Biopharmaceutics 2008 68(2):380-389
Autor:
Magnaghi, P., Casuscelli, F., Ardini, E., Parazzoli, A., Troiani, S., Valsasina, B., Texido, G., Casale, E., Avanzi, N., Orsini, P., Nuvoloni, S., Salom, B., Lombardi Borgia, A., Salsi, E., Saturno, G.S., Re Depaolini, S., Stellato, C., Montagnoli, A., Galvani, A., Isacchi, A.
Publikováno v:
In European Journal of Cancer October 2022 174 Supplement 1:S17-S17
Autor:
Daniele Donati, Andrea Lombardi Borgia, Ettore Perrone, Lucio Ceriani, Chiara Marchionni, Paolo Orsini, Marcella Nesi, Luisa Rusconi, Paola Magnaghi, Marina Fasolini, Nilla Avanzi, G. Canevari, Arturo Galvani, Maristella Colombo, Patrizia Banfi, Elena Ardini, Laura Buffa, Antonella Isacchi, Christian Orrenius, Roberto Bossi, Maria Beatrice Saccardo, Ermes Vanotti, Claudio Fiorelli, Francesco Fiorentini, Maria Menichincheri, Achille Panzeri, Luca Corti, Enrico Pesenti, Eduard R. Felder
Publikováno v:
Journal of Medicinal Chemistry. 59:3392-3408
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types. Despite the remarkable clinical activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resi
Autor:
Arturo Galvani, Roberto Cairoli, Matteo G. Della Porta, Alessandro Di Sanzo, Cristina Davite, Roberta Bosotti, Erika Ravelli, Francesco Fiorentini, Lucia Zanetta, Elena Colajori, Elena Ardini, Antonella Isacchi, Marina Ciomei, Frank Xiaodong Gan, Federico Lussana, Rosalinda Gatto, Giuseppe Rossi, Romana Pulci, Andrea Lombardi Borgia, Alessandro Rambaldi
Publikováno v:
Blood. 134:3855-3855
Background: NMS-03592088 is a novel, potent inhibitor of the FLT3, CSF1R and KIT receptor tyrosine kinases (KD < 1 nM for all three targets). The compound demonstrated high preclinical efficacy following oral administration in all tested target-depen
Autor:
Roberta Ceruti, Arturo Galvani, Gemma Texido Romero, Federico Lussana, Elena Ardini, Antonella Isacchi, Paola Gnocchi, Daniele Casero, Gianmaria Borleri, Nilla Avanzi, Wilma Pastori, Alessandro Rambaldi, Marina Ciomei, Andrea Lombardi Borgia, Laura Gianellini
Publikováno v:
Cancer Research. 79:1324-1324
NMS-P088 is a potent and selective inhibitor of FLT3 and KIT kinases, including variants with both primary as well as secondary resistance mutations, in particular retaining potent activity against residue 691 gatekeeper mutation which still represen
Autor:
Forte, Barbara1 (AUTHOR) barbara.forte@pharmacia.com, Lombardi-Borgia, Andrea1 (AUTHOR), Papeo, Gianluca1 (AUTHOR)
Publikováno v:
Synthetic Communications. 2003, Vol. 33 Issue 21, p3707-3716. 10p.
Autor:
Sabrina Cribioli, Rachele Alzani, Antonella Isacchi, M. Ciomei, Daniele Casero, Alessia Montagnoli, Daniele Donati, Arturo Galvani, Nadia Amboldi, A. Lombardi Borgia, Nilla Avanzi, L. Mancini, Wilma Pastori, Elena Ardini, Gemma Texido, M. Montemartini
Publikováno v:
European Journal of Cancer. 69:S127-S128
Autor:
Dario Ballinari, Arturo Galvani, Fabio Gasparri, Elena Ardini, Andrea Lombardi Borgia, Daniele Casero, Marina Ciomei, Gemma Texido, Nilla Avanzi, Sabrina Cribioli, Rachele Alzani, Antonella Isacchi, Daniele Donati, Wilma Pastori
Publikováno v:
Cancer Research. 78:805-805
FLT3, KIT and CSF1R are members of the class III receptor tyrosine kinase family, characterized by an autoinhibitory juxtamembrane (JM) domain that docks within the kinase domain to stabilize a catalytically inactive conformation. Activating rearrang
Autor:
Elena Ardini, Dario Ballinari, Eduard R. Felder, Alessandra Cirla, Paolo Polucci, Arturo Galvani, Patrizia Banfi, Antonella Isacchi, Ilaria Motto, Daniele Donati, Cinzia Cristiani, Nilla Avanzi, Andrea Lombardi Borgia, Maria Menichincheri, Matteo D'anello, Marina Ciomei
Publikováno v:
Cancer Research. 78:4785-4785
RET chromosomal rearrangements initially identified in a subset of papillary thyroid cancers, as well as gain-of-function point mutations present in ca. 70% of medullary thyroid carcinomas, are well established as oncogenic events that induce constit
Autor:
Hans Christian Korting, Katharina Ackermann, Karsten Rüdiger Mewes, S. Lombardi Borgia, Monika Schäfer-Korting
Publikováno v:
Skin Pharmacology and Physiology. 23:105-112
In recent years many efforts have been made to replace dermal toxicity testing of chemicals in the animal by in vitro assays. As a member of a German research consortium, we have previously contributed to the validation of an in vitro test protocol f